Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a scientific journal. GRI Bio’s 200-page annual report is packed with clinical trial data, cash-burn tables, and complex immune-modulation science that investors need but rarely have time to dissect. If you have ever searched for “GRI Bio SEC filings explained simply” or wondered how to spot financing risk in the next “GRI Bio quarterly earnings report 10-Q filing,” you are not alone.
Stock Titan solves that problem. Our AI reviews every GRI Bio document the moment it hits EDGAR, turning dense disclosures into plain-language briefs. Whether it is a “GRI Bio 8-K material events explained” alert on a Phase 2 trial, or “GRI Bio insider trading Form 4 transactions” highlighting real-time executive stock moves, you see the key points first.
Here is how investors use the page:
- Scan AI-powered summaries of the latest 10-K to find R&D spend, clinical milestones, and cash runway—“GRI Bio annual report 10-K simplified.”
- Compare quarter-over-quarter trial expenses with instant context inside each 10-Q—our “GRI Bio earnings report filing analysis.”
- Set alerts for “GRI Bio executive stock transactions Form 4” to monitor confidence ahead of pivotal readouts.
- Review the proxy to understand “GRI Bio proxy statement executive compensation” without wading through legal jargon.
All filing types—10-K, 10-Q, 8-K, S-1, Form 4—update in real time. And because our platform explains immunotherapy terminology, you will finally feel comfortable “understanding GRI Bio SEC documents with AI.” Skip the scrolling; focus on decisions.
GRI Bio is a clinical-stage biopharmaceutical company advancing oral iNKT/dNKT modulators. The company reported a net loss of $2.89 million for the quarter and $5.94 million for the six months ended June 30, 2025, driven by higher research and development spending on GRI-0621 ($1.88 million in Q2; $3.52 million six months) and ongoing company overhead.
Cash and cash equivalents were $5.12 million at period end; management forecasts this funding will support operations into the fourth quarter of 2025 but discloses substantial doubt about going concern without additional financing. Clinical progress includes completion of Phase 2a enrollment in July 2025, an Independent Data Monitoring Committee review reporting no safety concerns for early cohorts, and topline biomarker results expected in Q3 2025. Recent financings include an April 2025 offering (net $4.02 million) and ATM sales (net $4.29 million through June 30, 2025). The company disclosed a material weakness in internal controls.
GRI Bio, Inc. filed a Form S-8 to register an additional 400,000 shares of common stock reserved for issuance under its Amended and Restated 2018 Equity Incentive Plan. The filing incorporates prior Form S-8 registrations by reference and includes the amended plan and related award agreement forms as exhibits. The registration increases the pool available for employee stock awards but does not disclose total shares outstanding or quantify potential dilution.
GRI Bio, Inc. reported results from its August 13, 2025 virtual Annual Meeting. Stockholders approved an amendment to the Amended and Restated 2018 Equity Incentive Plan, increasing the number of shares reserved for issuance by 400,000 shares. The company noted 2,496,800 shares issued and outstanding as of the July 8, 2025 record date and a quorum of 1,090,373 shares (approximately 43.67%) was present or represented.
At the meeting the board nominees Roelof Rongen and Camilla V. Simpson were elected with 63,031 and 63,581 votes for, respectively, and the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal 2025 was ratified with 1,072,167 votes for. Exhibit 10.1 contains the amended equity incentive plan text.
GRI Bio (Nasdaq: GRI) furnished an 8-K under Item 7.01 disclosing a press release that reports interim safety results from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis. The disclosure is provided solely for Regulation FD purposes and is expressly not deemed “filed” under the Exchange Act. No efficacy data, financial metrics, or guidance updates were included. Exhibit 99.1 contains the full press release; no other material items were reported.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
